Treatment of Pulmonary Arterial Hypertension (PAH)

This review discusses the evidence in support of the use of macitentan (Opsumit®), a novel
dual endothelin receptor antagonist (ERA), in the treatment of pulmonary arterial hypertension
(PAH).

Please login below to download this issue (PDF)

Subscribe